🎀 GYN Oncology — 2026-W40

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Systematic review and meta-analysis of phase 3 RCTs of checkpoint inhibitor combinations in advanced ovarian cancer, published in Cancers (Basel). Finds that adding bevacizumab (and possibly PARP inhibitors) to ICIs improves progression-free survival while chemo-ICI combinations do not, informing which combination partners may be worth pursuing.

Updated 2025 clinical practice guideline from the Japan Society of Gynecologic Oncology for ovarian, fallopian tube, and primary peritoneal cancer, published in the Journal of Gynecologic Oncology. Revises recommendations on HRD/genomic testing, PARP inhibitor and bevacizumab maintenance, and surgical strategy, directly shaping systemic therapy decisions.

Randomized phase 2 trial comparing neoadjuvant mitomycin C/cisplatin versus paclitaxel/carboplatin specifically in BRCA1-associated advanced ovarian cancer, published in Int J Cancer. Explores an alternative neoadjuvant regimen in a rare, biomarker-defined population, informing surgical cytoreduction outcomes though survival differences were not significant.

Narrative review in Frontiers in Oncology summarizing prognostic and therapeutic implications of BRCA1/2 mutations in ovarian cancer. Consolidates evidence on platinum sensitivity and PARP inhibitor efficacy relevant to treatment selection.

Narrative review in Curr Oncol on hereditary breast-ovarian cancer genes beyond BRCA1/2. Highlights how germline PALB2, RAD51C, and RAD51D variants confer sensitivity to PARP inhibitors, informing genetic testing panels and targeted therapy selection.

Protocol description of a randomized phase 2 trial combining neoadjuvant chemo-immunotherapy, HIPEC, and maintenance pembrolizumab with or without olaparib in advanced epithelial ovarian cancer, published in Gynecologic Oncology. No efficacy results reported yet; informs an emerging multimodal treatment strategy under investigation.

Retrospective registry analysis linking community social vulnerability to clinical trial availability in ovarian cancer, published in Gynecologic Oncology. Highlights disparities in trial access that could inform efforts to improve equitable enrollment, though it does not directly change treatment decisions.

Retrospective institutional cohort study in Gynecologic Oncology comparing HER2 scoring concordance between biopsy and hysterectomy specimens in high-grade endometrial cancer. Finds substantial discordance that could alter eligibility for HER2-directed therapy, suggesting caution in relying on a single specimen type for biomarker-driven treatment decisions.

Multicenter retrospective cohort study in Korean patients with advanced ovarian cancer receiving first-line niraparib maintenance, published in J Gynecol Oncol. Supports real-world PFS/OS benefit of niraparib maintenance across BRCA subgroups, reinforcing current practice.

Retrospective cohort study in advanced high-grade serous ovarian cancer treated with neoadjuvant chemotherapy, published in Cancers. Suggests chemotherapy response score may help identify which patients derive survival benefit from sustained bevacizumab, offering a potential biomarker for treatment selection.